Nasopharyngeal carcinoma

The Lancet

Volumn 387, Issue 10022, 2016, Pages 1012-1024

  Chua, Melvin L K ^a,b   Wee, Joseph T S ^a,b   Hui, Edwin P ^c   Chan, Anthony T C ^c  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; OXALIPLATIN; PACLITAXEL; UFT;

ALCOHOL CONSUMPTION; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CHEMORADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DIET; DISEASE SURVEILLANCE; DISTANT FAILURE FREE SURVIVAL; DISTANT METASTASIS FREE SURVIVAL; EPISTAXIS; EPSTEIN BARR VIRUS INFECTION; FOOD PRESERVATION; GENETIC SUSCEPTIBILITY; HUMAN; LIVER METASTASIS; LOCAL RECURRENCE FREE SURVIVAL; MASS SCREENING; MOLECULARLY TARGETED THERAPY; NASOPHARYNX CARCINOMA; NOSE OBSTRUCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PAPILLOMAVIRUS INFECTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT DISEASE; RISK FACTOR; SMOKING HABIT; SURVIVAL RATE; NASOPHARYNGEAL NEOPLASMS;

HUMANS; NASOPHARYNGEAL NEOPLASMS;

EID: 84960109745     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)00055-0     Document Type: Conference Paper

References (145)

1. J Ferlay, I Soerjomataram, M Ervik et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11 http://globocan.iarc.fr/Default.aspx (accessed Aug 25, 2015).
2. JT Wee, TC Ha, SL Loong et al. Is nasopharyngeal cancer really a "Cantonese cancer"? Chin J Cancer 29 2010 517 526
3. JKC Chan, F Bray, P McCarron et al. Nasopharyngeal carcinoma L Barnes JW Eveson P Reichart WHO classification of tumours. Pathology and genetics of head and neck tumours 2005 IARC Press Lyon 85 97
4. WI Wei, JS Sham Nasopharyngeal carcinoma Lancet 365 2005 2041 2054
5. JM Nicholls Nasopharyngeal carcinoma: Classification and histological appearances Adv Anat Path 4 1997 71 84
6. R Pathmanathan, U Prasad, R Sadler, K Flynn, N Raab-Traub Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma N Engl J Med 333 1995 693 698
7. AS Chan, KF To, KW Lo et al. High frequency of chromosome 3p deletion in histologically normal nasopharyngeal epithelia from southern Chinese Cancer Res 60 2000 5365 5370
8. KW Lo, GT Chung, KF To Deciphering the molecular genetic basis of NPC through molecular, cytogenetic, and epigenetic approaches Semin Cancer Biol 22 2012 79 86
9. CM Tsang, YL Yip, KW Lo et al. Cyclin D1 overexpression supports stable EBV infection in nasopharyngeal epithelial cells Proc Natl Acad Sci USA 109 2012 E3473 E3482
10. LS Young, AB Rickinson Epstein-Barr virus: 40 years on Nat Rev Cancer 4 2004 757 768
11. CE Birdwell, KJ Queen, PC Kilgore et al. Genome-wide DNA methylation as an epigenetic consequence of Epstein-Barr virus infection of immortalized keratinocytes J Virol 88 2014 11442 11458
12. JH Maxwell, B Kumar, FY Feng et al. HPV-positive/p16-positive/EBV-negative nasopharyngeal carcinoma in white North Americans Head Neck 32 2010 562 567
13. YH Chan, CM Lo, HY Lau, TH Lam Vertically transmitted nasopharyngeal infection of the human papillomavirus: Does it play an aetiological role in nasopharyngeal cancer? Oral Oncol 50 2014 326 329
14. S Dogan, ML Hedberg, RL Ferris et al. Human papillomavirus and Epstein-Barr virus in nasopharyngeal carcinoma in a low-incidence population Head Neck 36 2014 511 516
15. Z Lin, B Khong, S Kwok et al. Human papillomavirus 16 detected in nasopharyngeal carcinomas in white Americans but not in endemic Southern Chinese patients Head Neck 36 2014 709 714
16. MH Stenmark, JB McHugh, M Schipper et al. Nonendemic HPV-positive nasopharyngeal carcinoma: Association with poor prognosis Int J Radiat Oncol Biol Phys 88 2014 580 588
17. JX Bei, WH Jia, YX Zeng Familial and large-scale case-control studies identify genes associated with nasopharyngeal carcinoma Semin Cancer Biol 22 2012 96 106
18. A Hildesheim, CP Wang Genetic predisposition factors and nasopharyngeal carcinoma risk: A review of epidemiological association studies, 2000-2011: Rosetta Stone for NPC: genetics, viral infection, and other environmental factors Semin Cancer Biol 22 2012 107 116
19. KP Tse, WH Su, KP Chang et al. Genome-wide association study reveals multiple nasopharyngeal carcinoma-associated loci within the HLA region at chromosome 6p21.3 Am J Hum Genet 85 2009 194 203
20. JX Bei, Y Li, WH Jia et al. A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci Nat Genet 42 2010 599 603
21. M Zhao, H Cai, X Li et al. Further evidence for the existence of major susceptibility of nasopharyngeal carcinoma in the region near HLA-A locus in Southern Chinese J Transl Med 10 2012 57
22. M Tang, JA Lautenberger, X Gao et al. The principal genetic determinants for nasopharyngeal carcinoma in China involve the HLA class I antigen recognition groove PLoS Genet 8 2012 e1003103
23. WL Hsu, KP Tse, S Liang et al. Evaluation of human leukocyte antigen-A (HLA-A), other non-HLA markers on chromosome 6p21 and risk of nasopharyngeal carcinoma PLoS One 7 2012 e42767
24. YM Chin, T Mushiroda, A Takahashi the Malaysian NPC Study Group HLA-A SNPs and amino acid variants are associated with nasopharyngeal carcinoma in Malaysian Chinese Int J Cancer 136 2015 678 687
25. JM Yee Ko, W Dai, EH Wun Wong et al. Multigene pathway-based analyses identify nasopharyngeal carcinoma risk associations for cumulative adverse effects of TERT-CLPTM1L and DNA double-strand breaks repair Int J Cancer 135 2014 1634 1645
26. X Guo, RC Johnson, H Deng et al. Evaluation of nonviral risk factors for nasopharyngeal carcinoma in a high-risk population of southern China Int J Cancer 124 2009 2942 2947
27. Xu FH, Xiong D, Xu YF, et al. An epidemiological and molecular study of the relationship between smoking, risk of nasopharyngeal carcinoma, and Epstein-Barr virus activation. J Natl Cancer Inst; 104: 1396-410.
28. KJ Yu, WL Hsu, RM Pfeiffer et al. Prognostic utility of anti-EBV antibody testing for defining NPC risk among individuals from high-risk NPC families Clin Cancer Res 17 2011 1906 1914
29. SM Cao, Z Liu, WH Jia et al. Fluctuations of Epstein-Barr virus serological antibodies and risk for nasopharyngeal carcinoma: A prospective screening study with a 20-year follow-up PLoS One 6 2011 e19100
30. SF Leung, JS Tam, AT Chan et al. Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody Clin Chem 50 2004 339 345
31. L Tang, Y Mao, L Liu et al. The volume to be irradiated during selective neck irradiation in nasopharyngeal carcinoma: Analysis of the spread patterns in lymph nodes by magnetic resonance imaging Cancer 115 2009 680 688
32. YM Lo, LY Chan, KW Lo et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma Cancer Res 59 1999 1188 1191
33. JY Shao, YH Li, HY Gao et al. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma Cancer 100 2004 1162 1170
34. Sobin LH, Gospodarowicz M, Wittekind C. 2010. Pharynx. TNM Online 2010; 30-38.
35. SS Guo, PY Huang, QY Chen et al. The impact of smoking on the clinical outcome of locoregionally advanced nasopharyngeal carcinoma after chemoradiotherapy Radiat Oncol 9 2014 246
36. H Jin, X Xie, H Wang et al. ERCC1 Cys8092Ala and XRCC1 Arg399Gln polymorphisms predict progression-free survival after curative radiotherapy for nasopharyngeal carcinoma PLoS One 9 2014 e101256
37. CS Chia, WS Ong, XJ Li et al. Serglycin expression: An independent marker of distant metastases in nasopharyngeal carcinoma Head Neck 2014 10.1002/hed.23841 published online July 3.
38. DC Lin, X Meng, M Hazawa et al. The genomic landscape of nasopharyngeal carcinoma Nat Genet 46 2014 866 871
39. P Zhang, SK Wu, Y Wang et al. p53, MDM2, eIF4E and EGFR expression in nasopharyngeal carcinoma and their correlation with clinicopathological characteristics and prognosis: A retrospective study Oncol Lett 9 2015 113 118
40. YM Lo, LY Chan, AT Chan et al. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma Cancer Res 59 1999 5452 5455
41. WY Wang, CW Twu, HH Chen et al. Long-term survival analysis of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA levels Cancer 119 2013 963 970
42. LQ Tang, QY Chen, SS Guo et al. The impact of plasma Epstein-Barr virus DNA and fibrinogen on nasopharyngeal carcinoma prognosis: An observational study Br J Cancer 111 2014 1102 1111
43. WH Chen, LQ Tang, FW Wang et al. Elevated levels of plasma D-dimer predict a worse outcome in patients with nasopharyngeal carcinoma BMC Cancer 14 2014 583
44. LQ Tang, CF Li, QY Chen et al. High-sensitivity C-reactive protein complements plasma Epstein-Barr virus deoxyribonucleic acid prognostication in nasopharyngeal carcinoma: A large-scale retrospective and prospective cohort study Int J Radiat Oncol Biol Phys 91 2015 325 336
45. V Lai, X Li, VH Lee et al. Nasopharyngeal carcinoma: Comparison of diffusion and perfusion characteristics between different tumour stages using intravoxel incoherent motion MR imaging Eur Radiol 24 2014 176 183
46. 18F-FDG PET parameters and plasma Epstein-Barr virus DNA load in patients with nasopharyngeal carcinoma J Nucl Med 53 2012 21 28
47. Z Yang, Q Shi, Y Zhang et al. Pretreatment (18) F-FDG uptake heterogeneity can predict survival in patients with locally advanced nasopharyngeal carcinoma - a retrospective study Radiat Oncol 10 2015 4
48. 18F-FDG-PET/CT for the detection of intracranial disease extension in nasopharyngeal carcinoma Head Neck Oncol 4 2012 49
49. BA Vellayappan, YY Soon, A Earnest et al. Accuracy of (18)F-flurodeoxyglucose-positron emission tomography/computed tomography in the staging of newly diagnosed nasopharyngeal carcinoma: A systematic review and meta-analysis Radiol Oncol 48 2014 331 338
50. ML Chua, SC Ong, JT Wee et al. Comparison of 4 modalities for distant metastasis staging in endemic nasopharyngeal carcinoma Head Neck 31 2009 346 354
51. MC Chang, JH Chen, JA Liang et al. Accuracy of whole-body FDG-PET and FDG-PET/CT in M staging of nasopharyngeal carcinoma: A systematic review and meta-analysis Eur J Radiol 82 2013 366 373
52. LQ Tang, QY Chen, W Fan et al. Prospective study of tailoring whole-body dual-modality [18F]fluorodeoxyglucose positron emission tomography/computed tomography with plasma Epstein-Barr virus DNA for detecting distant metastasis in endemic nasopharyngeal carcinoma at initial staging J Clin Oncol 31 2013 2861 2869
53. JK Tuan, TC Ha, WS Ong et al. Late toxicities after conventional radiation therapy alone for nasopharyngeal carcinoma Radiother Oncol 104 2012 305 311
54. N Lee, J Harris, AS Garden et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: Radiation therapy oncology group phase II trial 0225 J Clin Oncol 27 2009 3684 3690
55. IW Tham, SW Hee, RM Yeo et al. Treatment of nasopharyngeal carcinoma using intensity-modulated radiotherapy-the National Cancer Centre Singapore experience Int J Radiat Oncol Biol Phys 75 2009 1481 1486
56. G Peng, T Wang, KY Yang et al. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma Radiother Oncol 104 2012 286 293
57. AW Lee, WT Ng, LL Chan et al. Evolution of treatment for nasopharyngeal cancer - success and setback in the intensity-modulated radiotherapy era Radiother Oncol 110 2014 377 384
58. PM Teo, SF Leung, AT Chan et al. Final report of a randomized trial on altered-fractionated radiotherapy in nasopharyngeal carcinoma prematurely terminated by significant increase in neurologic complications Int J Radiat Oncol Biol Phys 48 2000 1311 1322
59. J Daoud, N Toumi, W Siala et al. Results of a prospective randomised trial comparing conventional radiotherapy to split course bifractionated radiation therapy in patients with nasopharyngeal carcinoma Radiother Oncol 85 2007 17 23
60. ZQ Pan, XY He, XM Guo et al. A phase III study of late course accelerated hyperfractionated radiotherapy versus conventionally fractionated radiotherapy in patients with nasopharyngeal carcinoma Am J Clin Oncol 35 2012 600 605
61. AW Lee, SY Tung, AT Chan et al. A randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma Radiother Oncol 98 2011 15 22
62. AW Lee, RK Ngan, SY Tung et al. Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma Cancer 121 2015 1328 1338
63. Al-Sarraf M, LeBlanc M, Giri PG, et al. Superiority of five year survival with chemo-radiotherapy (CT-RT) vs radiotherapy in patients with locally advanced nasopharyngeal cancer (NPC), Intergroup (0099) (SWOG 8892, RTOG 8817, ECOG 2388) phase III study: Final report. 37th Annual Meeting of the American Society of Clinical Oncology; San Francisco, CA, USA; May 12-15, 2001. Abstract 905.
64. J Wee, EH Tan, BC Tai et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety J Clin Oncol 23 2005 6730 6738
65. AW Lee, SY Tung, DT Chua et al. Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma J Natl Cancer Inst 102 2010 1188 1198
66. Y Chen, Y Sun, SB Liang et al. Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of China Cancer 119 2013 2230 2238
67. JC Lin, JS Jan, CY Hsu et al. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: Positive effect on overall and progression-free survival J Clin Oncol 21 2003 631 637
68. AT Chan, SF Leung, RK Ngan et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma J Natl Cancer Inst 97 2005 536 539
69. DL Kwong, JT Sham, GK Au Five-year update on a randomized factorial study on concurrent and adjuvant chemotherapy for advanced nasopharyngeal carcinoma Int J Radiat Oncol Biol Phys 66 suppl 2006 S15 S16
70. X Wu, PY Huang, PJ Peng et al. Long-term follow-up of a phase III study comparing radiotherapy with or without weekly oxaliplatin for locoregionally advanced nasopharyngeal carcinoma Ann Oncol 24 2013 2131 2136
71. QY Chen, YF Wen, L Guo et al. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: Phase III randomized trial J Natl Cancer Inst 103 2011 1761 1770
72. CJ Tao, L Lin, GQ Zhou et al. Comparison of long-term survival and toxicity of cisplatin delivered weekly versus every three weeks concurrently with intensity-modulated radiotherapy in nasopharyngeal carcinoma PLoS One 9 2014 e110765
73. AW Lee, SY Tung, RK Ngan et al. Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: Combined analyses of NPC-9901 and NPC-9902 Trials Eur J Cancer 47 2011 656 666
74. HH Loong, BB Ma, SF Leung et al. Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma Radiother Oncol 104 2012 300 304
75. L Zhang, C Zhao, B Ghimire et al. The role of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population: A meta-analysis of the phase III randomized trials BMC Cancer 10 2010 558
76. YP Chen, ZX Wang, L Chen et al. A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma Ann Oncol 26 2015 205 211
77. P Blanchard, A Lee, S Marguet the MAC-NPC Collaborative Group Chemotherapy and radiotherapy in nasopharyngeal carcinoma: An update of the MAC-NPC meta-analysis Lancet Oncol 16 2015 645 655
78. L Chen, CS Hu, XZ Chen et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: A phase 3 multicentre randomised controlled trial Lancet Oncol 13 2012 163 171
79. CC Lin, TT Chen, CY Lin et al. Prognostic analysis of adjuvant chemotherapy in patients with nasopharyngeal carcinoma Future Oncol 9 2013 1469 1476
80. P Blanchard, A Lee, J Leclercq the MAC-NPC Collaborative Group What is the best treatment in nasopharyngeal carcinoma? An individual patient data network meta-analysis Radiother Oncol 114 suppl 1 2015 6 7
81. EP Hui, BB Ma, SF Leung et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma J Clin Oncol 27 2009 242 249
82. G Fountzilas, E Ciuleanu, M Bobos et al. Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: A randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation Ann Oncol 23 2012 427 435
83. T Tan, WT Lim, KW Fong et al. Concurrent chemo-radiation with or without induction gemcitabine, Carboplatin, and Paclitaxel: A randomized, phase 2/3 trial in locally advanced nasopharyngeal carcinoma Int J Radiat Oncol Biol Phys 91 2015 952 960
84. DT Chua, J Ma, JS Sham et al. Improvement of survival after addition of induction chemotherapy to radiotherapy in patients with early-stage nasopharyngeal carcinoma: Subgroup analysis of two phase III trials Int J Radiat Oncol Biol Phys 65 2006 1300 1306
85. AT Chan, BB Ma, YM Lo et al. Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA J Clin Oncol 22 2004 3053 3060
86. AW Lee, TK Yau, DH Wong et al. Treatment of stage IV(A-B) nasopharyngeal carcinoma by induction-concurrent chemoradiotherapy and accelerated fractionation Int J Radiat Oncol Biol Phys 63 2005 1331 1338
87. AM Lim, J Corry, M Collins et al. A phase II study of induction carboplatin and gemcitabine followed by chemoradiotherapy for the treatment of locally advanced nasopharyngeal carcinoma Oral Oncol 49 2013 468 474
88. L Kong, C Hu, X Niu et al. Neoadjuvant chemotherapy followed by concurrent chemoradiation for locoregionally advanced nasopharyngeal carcinoma: interim results from 2 prospective phase 2 clinical trials Cancer 119 2013 4111 4118
89. JC Lin, WM Liang, JS Jan et al. Another way to estimate outcome of advanced nasopharyngeal carcinoma - is concurrent chemoradiotherapy adequate? Int J Radiat Oncol Biol Phys 60 2004 156 164
90. QT Le, CD Jones, TK Yau et al. A comparison study of different PCR assays in measuring circulating plasma Epstein-Barr virus DNA levels in patients with nasopharyngeal carcinoma Clin Cancer Res 11 2005 5700 5707
91. JC Lin, WY Wang, WM Liang et al. Long-term prognostic effects of plasma Epstein-Barr virus DNA by minor groove binder-probe real-time quantitative PCR on nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy Int J Radiat Oncol Biol Phys 68 2007 1342 1348
92. SF Leung, KC Chan, BB Ma et al. Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma Ann Oncol 25 2014 1204 1208
93. CW Twu, WY Wang, CC Chen et al. Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid Int J Radiat Oncol Biol Phys 89 2014 21 29
94. AM Zhang, Y Fan, XX Wang et al. Increased treatment-related mortality with additional cisplatin-based chemotherapy in patients with nasopharyngeal carcinoma treated with standard radiotherapy Radiother Oncol 104 2012 279 285
95. X Sun, S Su, C Chen et al. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: An analysis of survival and treatment toxicities Radiother Oncol 110 2014 398 403
96. QT Le, HE Kim, CJ Schneider et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: A randomized, placebo-controlled study J Clin Oncol 29 2011 2808 2814
97. M Henke, M Alfonsi, P Foa et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: A randomized, placebo-controlled trial J Clin Oncol 29 2011 2815 2820
98. JL Leenstra, RC Miller, R Qin et al. Doxepin rinse versus placebo in the treatment of acute oral mucositis pain in patients receiving head and neck radiotherapy with or without chemotherapy: A phase III, randomized, double-blind trial (NCCTG-N09C6 [Alliance]) J Clin Oncol 32 2014 1571 1577
99. RL Hong, CY Lin, LL Ting et al. Comparison of clinical and molecular surveillance in patients with advanced nasopharyngeal carcinoma after primary therapy: the potential role of quantitative analysis of circulating Epstein-Barr virus DNA Cancer 100 2004 1429 1437
100. DL Kwong, J Nicholls, WI Wei et al. The time course of histologic remission after treatment of patients with nasopharyngeal carcinoma Cancer 85 1999 1446 1453
101. RF Yen, RL Hung, MH Pan et al. 18-fluoro-2-deoxyglucose positron emission tomography in detecting residual/recurrent nasopharyngeal carcinomas and comparison with magnetic resonance imaging Cancer 98 2003 283 287
102. T Liu, W Xu, WL Yan et al. FDG-PET, CT, MRI for diagnosis of local residual or recurrent nasopharyngeal carcinoma, which one is the best? A systematic review Radiother Oncol 85 2007 327 335
103. Y Chen, X Liu, D Zheng et al. Diffusion-weighted magnetic resonance imaging for early response assessment of chemoradiotherapy in patients with nasopharyngeal carcinoma Magn Reson Imaging 32 2014 630 637
104. J Hong, Y Yao, Y Zhang et al. Value of magnetic resonance diffusion-weighted imaging for the prediction of radiosensitivity in nasopharyngeal carcinoma Otolaryngol Head Neck Surg 149 2013 707 713
105. V Lai, X Li, VH Lee et al. Intravoxel incoherent motion MR imaging: Comparison of diffusion and perfusion characteristics between nasopharyngeal carcinoma and post-chemoradiation fibrosis Eur Radiol 23 2013 2793 2801
106. WW Lam, HY Yuen, KS Wong et al. Clinically underdetected asymptomatic and symptomatic carotid stenosis as a late complication of radiotherapy in Chinese nasopharyngeal carcinoma patients Head Neck 23 2001 780 784
107. CS Li, U Schminke, TY Tan Extracranial carotid artery disease in nasopharyngeal carcinoma patients with post-irradiation ischemic stroke Clin Neurol Neurosurg 112 2010 682 686
108. M Chua, O Whee Sze, J Wee et al. Plasma EBV DNA as a predictive biomarker in patients with endemic nasopharyngeal carcinoma treated with induction chemotherapy and concurrent chemoradiation therapy Int J Radiat Oncol Biol Phys 90 2014 S120 S121
109. EP Hui, BB Ma, KC Chan et al. Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma Cancer 2015 10.1002/cncr.29413 published online May 6.
110. W Hara, QT Le Individualizing treatment for patients with nasopharyngeal cancer Cancer 2015 10.1002/cncr.29418 published online May 6.
111. F Han, C Zhao, SM Huang et al. Long-term outcomes and prognostic factors of re-irradiation for locally recurrent nasopharyngeal carcinoma using intensity-modulated radiotherapy Clin Oncol (R Coll Radiol) 24 2012 569 576
112. YM Tian, YH Tian, L Zeng et al. Prognostic model for survival of local recurrent nasopharyngeal carcinoma with intensity-modulated radiotherapy Br J Cancer 110 2014 297 303
113. L Zeng, XM Sun, CY Chen et al. Comparative study on prophylactic irradiation to the whole neck and to the upper neck for patients with neck lymph node-negative nasopharyngeal carcinoma Head Neck 36 2014 687 693
114. JY Chan, VL Chow, ST Wong, WI Wei Surgical salvage for recurrent retropharyngeal lymph node metastasis in nasopharyngeal carcinoma Head Neck 35 2013 1726 1731
115. OS Chan, RK Ngan Individualized treatment in stage IVC nasopharyngeal carcinoma Oral Oncol 50 2014 791 797
116. EP Hui, SF Leung, JS Au et al. Lung metastasis alone in nasopharyngeal carcinoma: A relatively favorable prognostic group. A study by the Hong Kong Nasopharyngeal Carcinoma Study Group Cancer 101 2004 300 306
117. CC Pan, J Lu, JR Yu et al. Challenges in the modification of the M1 stage of the TNM staging system for nasopharyngeal carcinoma: A study of 1027 cases and review of the literature Exp Ther Med 4 2012 334 338
118. Y Jin, XY Cai, YC Cai et al. To build a prognostic score model containing indispensible tumour markers for metastatic nasopharyngeal carcinoma in an epidemic area Eur J Cancer 48 2012 882 888
119. Y Jin, X Ye, L Shao et al. Serum lactic dehydrogenase strongly predicts survival in metastatic nasopharyngeal carcinoma treated with palliative chemotherapy Eur J Cancer 49 2013 1619 1626
120. CC Pan, PH Wu, JR Yu et al. Comparative survival analysis in patients with pulmonary metastases from nasopharyngeal carcinoma treated with radiofrequency ablation Eur J Radiol 81 2012 e473 e477
121. L Zeng, YM Tian, Y Huang et al. Retrospective analysis of 234 nasopharyngeal carcinoma patients with distant metastasis at initial diagnosis: therapeutic approaches and prognostic factors PLoS One 9 2014 e108070
122. SS Leong, J Wee, MH Tay et al. Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: A phase II trial using a triplet combination Cancer 103 2005 569 575
123. Y Jin, YX Shi, XY Cai et al. Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma J Cancer Res Clin Oncol 138 2012 1717 1725
124. KF Foo, EH Tan, SS Leong et al. Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type Ann Oncol 13 2002 150 156
125. DT Chua, JS Sham, GK Au A phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy Oral Oncol 39 2003 361 366
126. J Ngeow, WT Lim, SS Leong et al. Docetaxel is effective in heavily pretreated patients with disseminated nasopharyngeal carcinoma Ann Oncol 22 2011 718 722
127. C Chen, FH Wang, ZQ Wang et al. Salvage gemcitabine-vinorelbine chemotherapy in patients with metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy Oral Oncol 48 2012 1146 1151
128. TK Yau, T Shum, AW Lee et al. A phase II study of pemetrexed combined with cisplatin in patients with recurrent or metastatic nanopharyngeal carcinoma Oral Oncol 48 2012 441 444
129. AT Chan, MM Hsu, BC Goh et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma J Clin Oncol 23 2005 3568 3576
130. EP Hui, VW Lui, CS Wong et al. Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma Invest New Drugs 29 2011 1123 1131
131. EP Hui, BB Ma, AD King et al. Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation Ann Oncol 22 2011 1280 1287
132. WT Lim, QS Ng, P Ivy et al. A phase II study of pazopanib in Asian patients with recurrent/metastatic nasopharyngeal carcinoma Clin Cancer Res 17 2011 5481 5489
133. Huang Y, Zhang L, Pan JJ, et al. A phase II, multicenter, open-label, single-arm trial of famitinib in patients with advanced recurrent and/or metastatic nasopharyngeal carcinoma (NPC) after two previous treatment regimens. 2013 ASCO Annual Meeting; Chicago, IL, USA; May 31-June 4, 2013. Abstract 6026.
134. EP Hui, WY Lui, WC Hui et al. Preclinical activity of axitinib and its associated change of serum biomarkers in nasopharyngeal carcinoma Cancer Res 72 2012 1373
135. JC Soria, E Deutsch Hemorrhage caused by antiangiogenic therapy within previously irradiated areas: Expected consequence of tumor shrinkage or a warning for antiangiogenic agents combined to radiotherapy? Ann Oncol 22 2011 1247 1249
136. CU Louis, K Straathof, CM Bollard et al. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma J Immunother 33 2010 983 990
137. WK Chia, WW Wang, M Teo et al. A phase II study evaluating the safety and efficacy of an adenovirus-ΔLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma Ann Oncol 23 2012 997 1005
138. WK Chia, M Teo, WW Wang et al. Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma Mol Ther 22 2014 132 139
139. C Smith, J Tsang, L Beagley et al. Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy Cancer Res 72 2012 1116 1125
140. GS Taylor, TA Haigh, NH Gudgeon et al. Dual stimulation of Epstein-Barr virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: Potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma J Virol 78 2004 768 778
141. EP Hui, GS Taylor, H Jia et al. Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients Cancer Res 73 2013 1676 1688
142. GS Taylor, H Jia, K Harrington et al. A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr virus (EBV) target antigens: A phase I trial in UK patients with EBV-positive cancer Clin Cancer Res 20 2014 5009 5022
143. W Fang, J Zhang, S Hong et al. EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: implications for oncotargeted therapy Oncotarget 5 2014 12189 12202
144. AW Lee, W Foo, O Mang et al. Changing epidemiology of nasopharyngeal carcinoma in Hong Kong over a 20-year period (1980-99): An encouraging reduction in both incidence and mortality Int J Cancer 103 2003 680 685
145. SM Cao, MJ Simons, CN Qian The prevalence and prevention of nasopharyngeal carcinoma in China Chin J Cancer 30 2011 114 119